




2019 North America Conference on Lung Cancer

October 10-12 | Chicago, Illinois, USA

Program Book



#NACLC19

naclc2019.IASLC.org

Join the IASLC today!

IASLC membership includes:

- Collaboration with global thoracic oncology thought leaders across all disciplines
- Access to the *Journal of Thoracic Oncology*
- Discounts to meetings and the annual IASLC World Conference on Lung Cancer

**To join,
visit the IASLC
booth in the
Exhibit Hall.**

**Already a member? Pick up
your member gift at the
IASLC booth**



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



Welcome	5	Scientific Program	
<hr/>		<hr/>	
IASLC, ILCF and Committees		Program at a Glance	24
<hr/>		Satellite Symposia	25
International Association for the Study of Lung Cancer (IASLC)	8	IASLC CME Accredited Scientific Program	
International Lung Cancer Foundation	9	Thursday, October 10, 2019	26
Conference Committees	10	Friday, October 11, 2019	27
Program Committees	10	Saturday, October 12, 2019	30
<hr/>		Poster Presentations	32
General Conference Information		Author Index	36
<hr/>		<hr/>	
Conference Venue	12	Advertiser and Exhibitor Information	40
General Conference Information	13	<hr/>	
Continuing Medical Education (CME) Information	16		
Information for Invited Speakers, Abstract and Poster Presenters	18		
NACLC 2019 Travel Awards	21		
<hr/>			

CONFERENCE SECRETARIAT



**International Conference
Services Ltd. (ICS)**
www.icsevents.com

Suite 300, 1201 West Pender Street
Vancouver, BC, Canada V6E 2V2

Phone: +1 604 681 2153
Fax: +1 604 681 1049

Global Offices
Vancouver, Toronto, Denver, London,
Barcelona, Vienna, Tokyo, Singapore

IASLC



**2019
North America**

Download the IASLC North America Conference App

Stay up to date with
everything at NACLC 2019!

Get 24-hour access to all
Conference related information

Access to full scientific program
information including abstracts

Available for iPhone, iPad,
and Android

Connect and network with
other delegates



IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Conquering Thoracic Cancers Worldwide



Welcome



WELCOME



 @IASLC

 iaslc.lung

 facebook.com/IASLC

 IASLC

 IASLC

#NACLC19

naclc2019.IASLC.org



Access
NACLC 2019
Sessions

Anytime,
Anywhere

Get the
NACLC 2019
virtual meeting via
LIBRARY.IASLC.ORG

Never miss out on
another presentation!

The NACLC 2019 Virtual Meeting includes:

- Abstracts
- Presentation slides



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



The NACLC 2019
Virtual Library is
included in your
Conference
registration.

Check your name badge
for your Access Code.

Welcome Message



Dear Colleagues, Friends, Sponsors and Exhibitors,

On behalf of the International Association for the Study of Lung Cancer (IASLC) we are pleased to welcome you to the **IASLC 2019 North America Conference on Lung Cancer (#NACLC19)** at the Fairmont Chicago Millennium Park. The North America Conference on Lung Cancer is a dynamic meeting with a long tradition and close to 400 participants will join us this year to discuss important topics related to thoracic malignancies. The conference is a fabulous opportunity to network across disciplines with other people with careers focused on thoracic malignancies and learn about the latest developments in prevention, detection and care with novel data presentations. We encourage you to actively participate in the discussions, engage with our industry supporters and join us for the poster viewing reception on Friday evening. We are also hosting a special networking lunch Women in Thoracic Oncology on Saturday, October 12 which all delegates are welcome to attend.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to NACLC and IASLC. Without them this conference would not be possible.

Thank you for joining us in Chicago.

We look forward to hosting all of you over the next couple of days.

Best Regards,



Everett Vokes & Giorgio Scagliotti,
NACLC 2019 Steering Committee Chairs



Heather Wakelee & Jyoti Patel,
NACLC 2019 Conference Co-Chairs



Now Calling for International Participation

Contribute data to the IASLC 9th Edition Lung Cancer Staging Project

Help change the landscape of lung cancer treatment for future patients!

- New clinical and molecular elements have been added
- International participation is crucial to the project's success
- The 9th Edition recommendations will be developed in 2022

TIMELINE:

The study consists of lung cancer patients diagnosed between January 1, 2011 and December 31, 2019. Cases may be submitted through 2019, with follow-up for survival through 2021.

For more information:
www.iaslc.org/staging



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

IASLC, ILCF and Committees



IASLC, ILCF AND COMMITTEES



 @IASLC

 iaslc.lung

 facebook.com/IASLC

 IASLC

 IASLC

#NACLC19

naclc2019.IASLC.org

International Association for the Study of Lung Cancer (IASLC)

IASLC



13100 East Colfax Avenue,
Unit 10

Aurora, Colorado 80011
United States of America

Phone 1-855-GO-IASLC
(1-855-464-2752)

Fax Membership
720-505-2176

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 7,500 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

IASLC Staff

Dave Mesko

Chief Executive Officer
dave.mesko@iaslc.org

John Skadow

Chief Financial Officer
john.skadow@iaslc.org

AnnMarie Estrada

Senior Director,
Corporate Relations;
Executive Director,
ILC Foundation
annmarie.estrada@iaslc.org

Kristin M. Richeimer

Senior Director,
Member Experience
kristin.richeimer@iaslc.org

Murry Wynes, PhD

Senior Director,
Scientific Affairs
murry.wynes@iaslc.org

Becky Bunn

Director,
Strategic Initiatives and
Public Relations;
Interim Director,
Communications and Marketing
becky.bunn@iaslc.org

Kathy Doherty

Director,
Human Resources
kathy.doherty@iaslc.org

Jacinta Wiens, PhD

Associate Director,
Scientific Affairs
jacinta.wiens@iaslc.org

Mary Todd

Managing Editor,
Journal of Thoracic Oncology
mary.todd@iaslc.org

Karen Muth

Executive Assistant
and Board Liaison
karen.muth@iaslc.org

Kristin Ito

Patient Advocacy Manager
kristin.ito@iaslc.org

Kelsey Wood

Membership Manager
kelsey.wood@iaslc.org

Adam Mohrbacher

Communications Manager
adam.mohrbacher@iaslc.org

Jeanette Stensgaard

Conference Planning Manager
jeanette.stensgaard@iaslc.org

Kexin Yu

Accountant
kexin.yu@iaslc.org

Stephanie Lenhart

Accounting Manager
stephanie.lenhart@iaslc.org

Jill Daigneault, PhD

Scientific Affairs
Project Manager
jill.daigneault@iaslc.org

Abigail Metzger

Corporate Relations
Coordinator
abigail.metzger@iaslc.org

Sara Lindsey

Administrative Assistant
sara.lindsey@iaslc.org

Kirsten Black, PhD

Educational Programs Manager
kirsten.black@iaslc.org

Julie Bishop

Committee Coordinator
julie.bishop@iaslc.org

Debbie Platek

Education Consultant
debbie.platek@iaslc.org



International Lung Cancer Foundation

International Lung Cancer Foundation Board 2019

Board of Directors

David Carbone, USA

Dave Mesko, USA

David R. Gandara, USA

Lauren Fisher, USA

Starting in 2019, the Foundation would like to announce its new name, the International Lung Cancer Foundation.

We wanted to share this exciting change with you, our members, and NACLC delegates. Please join us on this journey moving forward and thank you to all who have continued to support our endeavor to conquer thoracic cancers together!

IASLC Foundation **RELAUNCH!**

The IASLC Foundation has taken on a new name and a new look! The International Lung Cancer Foundation, *Inspiring Hope through Research*, aspires to cultivate innovation, dedication and inspiration to the lung cancer research space. Please join us on our journey and thank you to all who have continued to support us.

Together we will fight to conquer thoracic malignancies!

For more information please visit: [IASLC.org/ILCF](https://iaslc.org/ILCF)

**INTERNATIONAL
LUNG CANCER
FOUNDATION**



INSPIRING HOPE THROUGH RESEARCH



Conference Committees

Conference Chairs

Jyoti Patel
Heather Wakelee

Steering Committee

Everett Vokes
Giorgio Scagliotti

Program Committees

Community

Thomas Hensing, USA
Kurt Oettel, USA
Samir Witt, USA

Medical Oncology

Julie Brahmer, USA
Anna Farago, USA
Mary Jo Fidler, USA
Nasser Hanna, USA
Tician Leal, USA
Jyoti Patel, USA
Heather Wakelee, USA

Mesothelioma

Raffit Hassan, USA
Hedy Lee Kindler, USA

Nursing & Allied Health

Melissa Culligan, USA
Mary Ellen Hand, USA
Bonnie Labdi, USA
Kim Sivertsen, USA

Patient Advocacy

Ivy Elkins, USA
Jill Feldman, USA
Upal Basu Roy, USA

Pathology

Jeremy Segal, USA
Lynette Sholl, USA
Ignacio Wistuba, USA

Prevention, Tobacco Cessation, Screening and Early Detection

James Mulshine, USA
Avi Spira, USA
Matthew Steliga, USA
Robert Winn, USA

Pulmonology

George Eapen, USA
Peter Mazzone, USA
Tim Murgu, USA

Radiation Oncology

Steve Chmura, USA
Tim Kruser, USA
Umberto Ricardi, Italy
Kenneth Rosenzweig, USA


Surgery

Jessica Donington, USA
Chris Seder, USA
Matthew Steliga, USA

Translational Science

Patrick Forde, USA
Christine Lovly, USA

General Conference Information




GENERAL CONFERENCE INFORMATION



 @IASLC

 iaslc.lung

 facebook.com/IASLC

 IASLC

 IASLC

#NACLC19

naclc2019.IASLC.org


Conference Venue




CONFERENCE VENUE

- Fairmont Millennium Park Hotel Chicago
200 N Columbus Dr, Chicago, IL 60601, USA

Floorplans



LOBBY LEVEL



B2 LEVEL



General Conference Information

ONSITE REGISTRATION

● B1 Level

Thursday, October 10	15:00–19:30
Friday, October 11	07:00–16:00
Saturday, October 12	07:00–11:30

SPEAKER PREVIEW CENTER

● Imperial Parlor, B2 Level

Thursday, October 10	15:00–19:30
Friday, October 11	07:00–16:00
Saturday, October 12	07:00–11:30

EXHIBITION

● Exhibition & Poster Hall, B2 Level

Friday, October 11	09:30–18:00
Saturday, October 12	09:15–12:30

General Conference Information



IASLC NACLC 2019 MOBILE APP

Download the free IASLC 2019 NACLC official mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor biographies, and general Conference and venue information on our easy to use app!

The app is compatible with all iOS devices (iPhone, iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

Search for: **IASLC NACLC 2019**



IASLC VIRTUAL LIBRARY

All presentation slides and abstracts will be made available as a Virtual Meeting in the IASLC Virtual Library. The NACLC 2019 Virtual Meeting is included in your registration and can be accessed through library.iaslc.org.

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your NACLC 2019 registration confirmation email. After you enter your Access Code and confirm your account details, you'll be able to view any presentations that have been marked as "Now Available". To start viewing, please visit: library.iaslc.org



IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOW

 [@IASLC](https://twitter.com/IASLC)

 facebook.com/IASLC

 [iaslc.lung](https://www.instagram.com/iaslc.lung)

[#NACLC19](https://twitter.com/NACLC19)



ABSTRACTS

Accepted abstracts will be presented in Oral, Poster Discussion and Poster sessions. All presented abstracts will be published in a supplement of the *Journal of Thoracic Oncology* which will be posted online on the JTO website in November 2019.

ABSTRACTS ONLINE

Attendees are invited to view the abstracts in the Virtual Meeting available on the Conference website. The Virtual Meeting allows searching for abstracts, topics, presenters, sessions and keywords, selecting abstracts of interest and building your own personal conference calendar.

Visit library.iaslc.org

ACCREDITATION

→ Please see page 16 in this book for further information.

ATTIRE

Business casual is appropriate for all sessions. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

BADGES AND ACCESS CONTROL

Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.

BREAKFAST

A light breakfast will be provided in the session rooms from 07:00–08:00 on Friday and Saturday.

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CME ACCREDITATION AND CME CERTIFICATE

→ Please see page 16 in this book for further information.

PRAYER | LACTATION ROOM

● Royal Room, B2 Level

WIRELESS INTERNET

Wireless internet will be provided in the meeting and exhibit space.

Network: `Fairmont_Meeting`
Password: `IASLC2019`

Disclaimer

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

Continuing Medical Education (CME) Information

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Commercial SupportSM of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational program process—from development through implementation—to ensure independence of educational activities. IASLC policies are outlined below.

In compliance with ACCME Standards, each individual in a position to control the content of an educational activity must disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant” financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose relevant financial relationships are not allowed to have control of, or responsibility for, the development, management, presentation or evaluation of CME activities. All disclosures are reviewed for potential conflicts, and appropriate steps for resolution are taken when needed. Additionally, individuals must agree to comply with specific rules (attestations) to ensure content is balanced and evidence-based, does not promote the business interests of a commercial entity, and conforms to the generally accepted standard of experimental design, data collection and analysis. Presenters are also required to clearly identify any non-FDA approved uses of products. IASLC also monitors presentations for quality and compliance through direct observation (IASLC staff and CME committee members), and through member feedback on evaluation surveys.

For the IASLC 2019 North America Conference on Lung Cancer (NACLC 2019), disclosure information will be available for viewing on the conference website. Presenters are also required to include a disclosure slide listing all relevant financial relationships with commercial interests. CME related questions should be directed to IASLC at cme@iaslc.org.



CREDIT STATEMENT

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates this live activity for a maximum of 11 *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This conference is an educational and scientific event which will cover key aspects of the diagnosis and management of lung cancer and other thoracic malignancies. With a multi-disciplinary program including invited lectures, parallel oral abstracts sessions and poster presentations, participants will learn about prevention, screening and disparities in uptake of screening, surgical management, advanced radiation therapy techniques, novel therapeutics including targeted agents and immunotherapy, and the latest in diagnostics and pathology of lung cancer and other thoracic malignancies. Talks will cover multi-disciplinary implementation of the latest knowledge into daily practice.

TARGET AUDIENCE

The IASLC 2019 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants, nurses and other research professionals.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
2. Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
3. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
4. Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
5. Collaborate on multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
6. Engage and empower patients to become active participants in their treatment.

OFFICIAL LANGUAGE

The official language of the IASLC 2019 North America Conference on Lung Cancer is English.

DISCLAIMER

The information presented at the IASLC 2019 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



HOW TO RECEIVE A CME CERTIFICATE (PHYSICIANS ONLY)

Physicians are entitled to receive a CME certificate after completing the conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the conference; the survey can also be accessed from the conference website. After submitting the survey, physicians have the option to print or save their CME certificate.

The deadline for claiming CME credit is December 31, 2019. Please direct any certificate inquiries to: cme@iaslc.org

HOW TO RECEIVE A CERTIFICATE OF ATTENDANCE (NON-PHYSICIANS)

Non-physicians are entitled to receive a "Certificate of Attendance". To claim a Certificate of Attendance, non-physicians must first complete the conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the conference; the survey can also be accessed from the conference website. After submitting the survey, attendees may print or save their Certificate of Attendance.

The deadline for receiving a Certificate of Attendance is December 31, 2019. Please direct any certificate inquiries to: cme@iaslc.org



Information for Invited Speakers, Abstract and Poster Presenters



SPEAKER PREVIEW CENTER

● Imperial Parlor, B2 Level

Thursday, October 10	15:00–19:30
Friday, October 11	07:00–16:00
Saturday, October 12	07:00–11:30

DISCLOSURE INFORMATION

All speakers must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present.

PRESENTATION SLIDE TEMPLATE

All speakers are encouraged to use the IASLC/NACLC presentation slide template for their presentation.

SPEAKER PREVIEW CENTER

Please provide your presentation slides to the Speaker Preview Center at least 2 hours prior to your presentation. The use of personal laptops for presentations is not allowed as it can cause technical delays and cut into a presenter's time.

Poster Presentations

All Poster Presentation boards are located in the **Exhibition & Poster Hall, B2 Level**.

Each Poster Board is identified with a Poster Number that corresponds with the pre-assigned Poster Number published on the conference website, in this Program Book.

Poster Set Up Time

Friday, October 11	08:00–09:30
--------------------	-------------

Poster Take Down Time

Saturday, October 12	12:30–13:30
----------------------	-------------

Author Standby Time

Friday, October 11	16:45–18:00 (Poster Viewing Reception)
--------------------	---

NACLC 2019 Travel Awards

NACLC 2019 TRAVEL AWARDS

 @IASLC  iaslc.lung  facebook.com/IASLC  IASLC  IASLC

#NACLC19

naclc2019.IASLC.org

COMING THIS FALL!

Apply for Research Awards!

The Lung Cancer Foundation of America–Bristol Myers Squibb/ILCF Young Investigator Research Awards in Translational Immuno-oncology are two-year, \$200,000 grants focused on lung cancer research. There are two awards available.



Bristol-Myers Squibb



LCFA

Lung Cancer Foundation of America

The ILCF Fellowship and Young Investigator Awards are one-year, \$50,000 grants focused on lung cancer research. There are six awards available.

APPLICATIONS
OPEN:
October 14
December 15, 2019

INTERNATIONAL
LUNG CANCER
FOUNDATION



For more information, visit:
www.IASLC.org/research-education/fellowships

INSPIRING HOPE THROUGH RESEARCH

NACLC 2019 Travel Awards



Congratulations to our NACLC 2019 Travel Award Winners.

The Award Winners will be presented with their award during the General Session on **Friday, October 11 starting at 08:05 in the Imperial Ballroom.**

NWABUNDO ANUSIM

USA

P1.12: Demographics and Survival in Malignant Pleural Mesothelioma: Analysis of SEER Data

JAILEENE PEREZ-MORALES

USA

OA02.08: Peritumoral and Intratumoral Radiomic Features Identify Aggressive Screen-detected Early-stage Lung Cancers

LOVA SUN

USA

OA03.02: Outcomes of Patients with Metastatic Non-small Cell Lung Cancer (mNSCLC) with Brain Metastases Treated with Pembrolizumab

ILKE TUNALIA

USA

OA02.05: Clinical-radiomic Models Predict Overall Survival Among Non-small Cell Lung Cancer Patients Treated with Immunotherapy



Get Social!

JOIN THE CONVERSATION!

Official hashtag:
#NACLC19



@IASLC



facebook.com/IASLC



iaslc.lung

IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Conquering Thoracic Cancers Worldwide

Scientific Program

SCIENTIFIC PROGRAM

CHICAGO
CELTIC THUNDER
X TOUR
OCTOBER 14

CHICAGO
LIVE NATION & MSG PRESENT
CELTIC THUNDER

 @IASLC

 iaslc.lung

 facebook.com/IASLC

 IASLC

 IASLC

#NACLC19

naclc2019.IASLC.org

Program at a Glance

Program listings are subject to change.

THURSDAY | October 10, 2019

FRIDAY | October 11, 2019

SATURDAY | October 12, 2019

IMPERIAL BALLROOM, B2 LEVEL

ROUGE, LOBBY LEVEL

IMPERIAL BALLROOM, B2 LEVEL

ROUGE, LOBBY LEVEL

IMPERIAL BALLROOM, B2 LEVEL

ROUGE, LOBBY LEVEL

08:00					
08:30			Prevention, Early Detection and Patient Provider Partnerships (08:05-09:45)		Precision Medicine in Advanced Thoracic Tumors (08:15-09:15)
09:00					Multidisciplinary Approaches to Diagnosis and Treatment (08:15-09:15)
09:30					Poster Viewing and Networking Break (09:15-09:45)
10:00			Poster Viewing and Networking Break (09:45-10:15)		
10:30			Biomarkers in 2019 and Beyond (10:15-11:15)	Patient Selection for Local Therapies in the Era of Immunotherapy (10:15-11:15)	Oral Abstract Session 2: Screening and IO Toxicity (09:45-11:15)
11:00					Oral Abstract Session 3: IO Concerns and Targeted Therapies (09:45-11:15)
11:30					
12:00			Lunch Break (11:15-12:45)		Closing Plenary (11:30-12:30)
12:30					
13:00			Keynote Session with Douglas R. Lowy (12:45-13:45)		Women in Thoracic Oncology Networking Lunch (12:30-13:30)
13:30					
14:00			Networking Break (13:45-14:00)		
14:30			Oral Abstract Session 1: Precision Medicine and Personalized Therapy for Lung Cancer (14:00-15:30)		
15:00					
15:30			Networking Break (15:30-15:45)		
16:00			Poster Discussion Session 1 (15:45-16:45)		
16:30					
17:00			Poster Viewing Reception (16:45-18:00)		
17:30		Welcome Reception (17:00-18:00)			
18:00					
18:30		Opening Keynote Lectures (18:00-19:30)			
19:00					
19:30					

PROGRAM AT A GLANCE

SCIENTIFIC PROGRAM

Satellite Symposia Friday, October 11

11:30 – 12:30 SYMPOSIUM BY RESEARCH TO PRACTICE:

Meet the Professors – Clinical Investigators
Provide Perspectives on the Integration
of Immune Checkpoint Inhibitors into the
Management of Small Cell Lung Cancer

● Rouge, Lobby Level

11:15 – 11:30 Registration and Lunch Buffet

11:30 – 12:30 Educational Program

Faculty: Anna F. Farago, MD, PhD,
Ramaswamy Govindan, MD

Moderator: David R. Spigel, MD



Research To Practice is accredited by
the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.

*This activity is supported by an
educational grant from AstraZeneca
Pharmaceuticals LP.*

This program was approved by the
IASLC 2019 North America Conference
on Lung Cancer Program Committee
as an independent activity held in
conjunction with the IASLC 2019 North
America Conference on Lung Cancer.
This program is not sponsored or
endorsed by IASLC and is not part of
the official IASLC accredited program.

18:00 – 19:45 SYMPOSIUM BY RESEARCH TO PRACTICE:

Consensus or Controversy? – Addressing
Practical Clinical Questions Across the
Metastatic Lung Cancer Continuum

● Rouge, Lobby Level

17:45 – 18:15 Registration and Dinner Buffet

18:15 – 19:45 Educational Program

Faculty: Nasser H. Hanna, MD,
Leora Horn, MD, MSc,
Lecia V. Sequist, MD, MPH

Moderator: Joel W. Neal, MD, PhD



Research To Practice is accredited by
the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.

*This activity is supported by an
educational grant from Genentech.*

This program was approved by the
IASLC 2019 North America Conference
on Lung Cancer Program Committee
as an independent activity held in
conjunction with the IASLC 2019 North
America Conference on Lung Cancer.
This program is not sponsored or
endorsed by IASLC and is not part of
the official IASLC accredited program.



IASLC CME Accredited Scientific Program

Thursday, October 10, 2019

15:00–19:30 **Registration Open**

- B1 Level

15:00–18:30 **Speaker Preview Center Open**

- Imperial Parlor, B2 Level

17:00–18:00 **WELCOME RECEPTION**

- Rouge, Lobby Level

GS01

18:00–19:30 **GS01: OPENING & KEYNOTE LECTURES**

- Rouge, Lobby Level

Chairs: Heather Wakelee, USA & Jyoti Patel, USA

18:00–18:05 **GS01.01: Welcome**

Everett Vokes, USA & Jyoti Patel, USA

18:05–18:10 **GS01.02: Welcome from the IASLC President Elect**

Heather Wakelee, USA

18:10–18:30 **GS01.03: Screening**

Claudia Henschke, USA

18:30–18:35 **GS01.04: Q&A**

18:35–18:55 **GS01.05: Disparities in Screening**

Patricia Rivera, USA

18:55–19:00 **GS01.06: Q&A**

19:00–19:20 **GS01.07: IO + Chemo vs IO Alone in PD-L1 1-49% and PD-L1 50%**

Ramaswamy Govindan, USA vs Hossein Borghaei, USA

19:20–19:30 **Q&A**

IASLC CME Accredited Scientific Program

Friday, October 11, 2019



07:00–16:00 Registration Open
● B1 Level

07:00–16:00 Speaker Preview Center Open
● Imperial Parlor, B2 Level

07:00–08:00 BREAKFAST
● Exhibition and Poster Hall, B2 Level

GS02

- 08:05–09:45 GS02: PREVENTION, EARLY DETECTION AND PATIENT PROVIDER PARTNERSHIPS**
Chairs: Jill Feldman, USA & Nasser Hanna, USA
● Imperial Ballroom, B2 Level
- 08:05–08:10 GS02.01: Welcome and Travel Award Presentations**
- 08:10–08:25 GS02.02: Clinical Trial Shaping Our Next Step—Partnership between Investigators and Patients**
Karen Kelly, USA
- 08:25–08:35 GS02.03: Electronic Cigarettes and Vaping**
Anthony Alberg, USA
- 08:35–08:50 GS02.04: Imaging to Identify and Characterize Lung Nodules**
Herbert MacMahon, USA
- 08:50–09:00 GS02.05: Molecular Biomarkers in Early Detection of Lung Cancer**
Peter Mazzone, USA
- 09:00–09:10 GS02.06: How Lung Cancer Advocacy and Research Has Changed in the Past Years**
Jill Feldman, USA
- 09:10–09:20 GS02.07: The Increasing Importance of Social Media in Advocacy**
Brendon Stiles, USA
- 09:20–09:30 GS02.08: Financial Toxicity of Cancer Therapy**
Fumiko Chino, USA
- 09:30–09:45 GS02.09: Panel Discussion with all Speakers**

09:45–10:15 POSTER VIEWING AND NETWORKING BREAK
● Exhibition and Poster Hall, B2 Level

GS03

- 10:15–11:15 GS03: BIOMARKERS IN 2019 AND BEYOND**
Chairs: Charu Aggarwal, USA & Ticiana Leal, USA
● Imperial Ballroom, B2 Level
- 10:15–10:20 GS03.01: Introduction**
Charu Aggarwal, USA
- 10:20–10:30 GS03.02: Innovations in Broad Sequencing Including Fusion Detection and Cellularity Constraints**
Marc Ladanyi, USA
- 10:30–10:40 GS03.03: TMB Ready for Prime Time?**
John Longshore, USA
- 10:40–10:50 GS03.04: Incorporating Blood Biomarkers into Clinical Practice**
Charu Aggarwal, USA
- 10:50–11:00 GS03.05: Genomic Biomarkers of Immunotherapy Sensitivity and Resistance**
Ferdinandos Skoulidis, USA
- 11:00–11:15 GS03.06: Panel Discussion**

GS04

- 10:15–11:15 GS04: PATIENT SELECTION FOR LOCAL THERAPIES IN THE ERA OF IMMUNOTHERAPY**
Chairs: Jessica Donington, USA & Tim Kruser, USA
● Rouge, Lobby Level
- 10:15–10:20 GS04.01: Introduction**
Jessica Donington, USA
- 10:20–10:28 GS04.02: Pre-habilitation/Patient Selection and Enhanced Recovery after Surgery (ERAS)**
Katherine Kuhns, USA
- 10:28–10:36 GS04.03: Induction Strategies for Stage II/IIIA NSCLC Including Radiation and IO**
Jessica Donington, USA
- 10:36–10:44 GS04.04: Role of IO and SBRT for Inoperable Early Stage NSCLC**
Cliff Robinson, USA
- 10:44–10:52 GS04.05: Recurrence after SBRT**
Mara Antonoff, USA
- 10:52–11:00 GS04.06: Assessment and Management of IO Toxicity in Combined Modality Trials**
Mary Jo Fidler, USA
- 11:00–11:15 GS04.07: Panel Discussion**

11:15–12:45



LUNCH BREAK

● Exhibition and Poster Hall, B2 Level

GS05

12:45–13:45 GS05: KEYNOTE: NCI PERSPECTIVES: LUNG CANCER INITIATIVES

Chair: Everett Vokes, USA

● Imperial Ballroom, B2 Level

12:45–12:50 **GS05.01: Introduction**
Everett Vokes, USA

12:50–13:35 **GS05.02: NCI Perspectives: Lung Cancer Initiatives**
Douglas Lowy, NCI Acting Director, USA

13:35–13:45 Q&A

13:45–14:00



NETWORKING BREAK

● Exhibition and Poster Hall, B2 Level

OA01

14:00–15:30 OA01: ORAL ABSTRACT SESSION 1: PRECISION MEDICINE AND PERSONALIZED THERAPY FOR LUNG CANCER

Chairs: Nasser Hanna, USA & Heather Wakelee, USA

● Imperial Ballroom, B2 Level

14:00–14:07 **OA01.01: Pembrolizumab Plus Chemotherapy for Advanced NSCLC Without Tumor PD-L1 Expression: Pooled Analysis of KNO21G, KN189 and KN407**
Hossein Borghaei, USA

14:07–14:14 **OA01.02: Prognostic Value of Baseline Autoantibodies in Metastatic NSCLC Patients Receiving PD-/PDL-1 Targeted Immunotherapy**
Imad Tarhoni, USA

14:14–14:21 **OA01.03: Prognostic Role of NLR in Stage III NSCLC Undergoing Chemoradiation: Secondary Analysis of PROCLAIM trial**
Tithi Biswas, USA

14:21–14:28 **OA01.04: Safety and Efficacy of Flu Vaccination after Treatment with Immune Checkpoint Inhibitors: A Retrospective Review**
Nathan Roberts, USA

14:28–14:38 **OA01.05: Discussant: IO Prognostics Beyond PD-L1 and TMB**
Nasser Hanna, USA

14:38–14:43 **OA01.06: Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer**
Bob Li, USA

14:43–14:48

OA01.07: Capmatinib (INC280) in METΔex14-mutated Advanced NSCLC: Efficacy Data from the Phase 2 GEOMETRY Mono-1 Study
Rebecca S. Heist, USA

14:48–14:53

OA01.08: A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRm+/T790M+ Advanced or Recurrent NSCLC Patients
Yuankai Shi, China

14:53–15:03

OA01.09: Discussant
Jyoti Patel, USA

15:03–15:13

OA01.10: Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer
Matthew Smeltzer, USA

15:13–15:23

OA01.11: Discussant: NGS Path Forward with IASLC
Heather Wakelee, USA

15:23–15:30

Q&A

15:30–15:45



NETWORKING BREAK

● Exhibition and Poster Hall, B2 Level

PD01

15:45–16:45 PD01: POSTER DISCUSSION SESSION

Chairs: Leora Horn, USA and Heather Wakelee, USA

● Imperial Ballroom, B2 Level

15:45–15:55

PD01.01: Discussant: Practice Patterns: So Many Choices and Optimal Therapies
Kurt Oettel, USA

Posters to be discussed by Discussant:

PD01.02: Oncologists' Management of Advanced NSCLC: A Simulation-Based Performance Assessment

PD01.03: Changes in Immune Checkpoints Landscape Associated with TGF-β Induced EMT in Lung Adenocarcinoma

PD01.04: CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC

PD01.05: CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients

PD01.06: CANOPY-2: Phase 3 Study of Canakinumab plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC

- 15:55–16:05 **PD01.07:** Discussant: Novel Risk Prediction Strategies
Joel Neal, USA
- Posters to be discussed by Discussant:
- PD01.08:** Incidence and Predictors Associated with the Development of Peripheral Neuropathy in Non-Small Cell Lung Cancer Patients
- PD01.09:** Incidence and Predictors Associated with the Development of Pneumonitis In Non-Small Cell Lung Cancer Patients.
- PD01.10:** Diagnostic Non-Invasive Biopsy Can Substitute Conventional Tissue Dependent Procedures in Suspected Cases of Lung Cancer
- PD01.11:** Artificial Intelligence Can Detect Lung Cancer from High Resolution Microscopic Images of Conditioned Peripheral Blood
- 16:05–16:15 **PD01.12:** Discussant: Radiation in 2020 and Beyond
Kenneth Rosenzweig, USA
- Posters to be discussed by Discussant:
- PD01.13:** Stereotactic Modulating Radiation Therapy (SMRT) for Oligo-Metastatic Non-Small Cell Lung Cancer
- PD01.14:** Targeting the Chemoradiation Resistance of Lung Cancers with KRAS/TP53 Co-mutations
- PD01.15:** Raman Spectroscopy and NIR Spectroscopy as Possible Aid in Localisation of Solitary Pulmonary Nodules
- 16:15–16:25 **PD01.16:** Discussant: Quality Lung Cancer Care
Tim Kruser, USA
- Posters to be discussed by Discussant:
- PD01.17:** Successful Implementation of a Free Lung Cancer Screening Program in a Rural Tertiary Care Hospital Setting
- PD01.18:** Beneficial Effect of Antibiotic Use in Patients with Stage IV NSCLC Treated with Immune Checkpoint Inhibitors
- PD01.19:** Lung Cancer Strategist Program: A Novel Care Delivery Model to Improve Timeliness of Diagnosis and Treatment
- PD01.20:** Medicaid Outcome Inequalities in Small Cell Lung Cancer
- 16:25–16:45 Q&A

16:45–18:00  **P1: POSTER VIEWING RECEPTION**

● Exhibition and Poster Hall, B2 Level

Please note: Poster presentations are not certified for CME credit.



IASLC CME Accredited Scientific Program

Saturday, October 12, 2019

07:00–11:30 Registration Open
● B1 Level

07:00–11:30 Speaker Preview Center Open
● Imperial Parlor, B2 Level

07:15–08:15 BREAKFAST
● Exhibition and Poster Hall, B2 Level
Rouge, Lobby Level

GS06

08:15–09:15 GS06: PRECISION MEDICINE IN ADVANCED THORACIC TUMORS

Chairs: Lecia Sequist, USA & Hedy Lee Kindler, USA
● Imperial Ballroom, B2 Level

08:15–08:18 GS06.01: Introduction
Lecia Sequist, USA

08:18–08:25 GS06.02: Treatment of New and Emerging Driver Mutations
Paul Paik, USA

08:25–08:32 GS06.03: Updates in ALK
Caroline McCoach, USA

08:32–08:39 GS06.04: Progression after First Line Osimertinib
Lecia Sequist, USA

08:39–08:46 GS06.05: Clinical Trials in MPM
Hedy Lee Kindler, USA

08:46–08:52 GS06.06: SCLC - Updates
Anna Farago, USA

08:52–09:00 GS06.07: CNS Disease - Systemic Therapy as First Line: From a Radiation Oncology Perspective
Vinai Gondi, USA

09:00–09:15 GS06.08: Panel Discussion

GS07

08:15–09:15 GS07: MULTIDISCIPLINARY APPROACHES TO DIAGNOSIS AND TREATMENT

Chairs: Tim Murgu, USA & Elizabeth David, USA
● Rouge, Lobby Level

08:15–08:20 GS07.01: Introduction
Elizabeth David, USA

08:20–08:28 GS07.02: Rebiopsy after Progressive Disease, Pseudoprogression, Adjudication of Site Selection
Tim Murgu, USA

08:28–08:35 GS07.03: Management of Malignant Effusion (TKIs and IO)
Carla Lamb, USA

08:35–08:43 GS07.04: MPR Post Neo-adjuvant IO
Ignacio Wistuba, USA

08:43–08:51 GS07.05: Diagnostic and Management Dilemmas in Synchronous NSCLC
Elizabeth David, USA

08:51–08:59 GS07.06: Ablative Radiation Therapy for Operable Disease
Megan Daly, USA

08:59–09:15 GS07.07: Panel Discussion

09:15–09:45 POSTER VIEWING AND NETWORKING BREAK
● Exhibition and Poster Hall, B2 Level

OA02

09:45–11:15 OA02: ORAL ABSTRACT SESSION 2: SCREENING AND IO TOXICITY

Chairs: Ticiana Leal, USA & Sharyn Katz, USA
● Imperial Ballroom, B2 Level


09:45–09:52 OA02.01: Outcomes of Integrating Individualized Tobacco Cessation Counseling in a Lung Cancer Screening Program
John Pagteilan, USA

09:52–09:59 OA02.02: Outcomes of Smoking Cessation Counseling in a Surgical Clinic
Nicholas Tingquist, USA

09:59–10:06 OA02.03: CNS Metastasis as Exclusion Criteria in Clinical Trials Involving Extensive-Stage Small Cell Lung Cancer
Takefumi Komiya, USA

10:06–10:16 OA02.04: Discussant: Smoking Cessation and Inclusivity in Clinical Trials
Ticiana Leal, USA

10:16–10:26 OA02.05: Clinical-Radiomic Models Predict Overall Survival Among Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
Ilke Tunali, USA

- 10:26–10:33 **OA02.06:** Lung Cancer Screening in Patients with versus Without a Personal History of Cancer
Patricia Rivera, USA
- 10:33–10:40 **OA02.07:** Low Dose CT Lung Screening in First Responders
Vershalee Shukla, USA
- 10:40–10:47  **OA02.08:** Peritumoral and Intratumoral Radiomic Features Identify Aggressive Screen-Detected Early-Stage Lung Cancers
Jaileene Perez Morales, USA
- 10:47–10:54 **OA02.09:** Multi-Planar Lung Cancer Measurements Provide Improved Accuracy in Clinical Staging
Erin M. Corsini, USA
- 10:54–11:04 **OA02.10:** Discussant: Radiomics, Screening and Imaging
Sharyn Katz, USA
- 11:04–11:15 Q&A

 **OA03**

- 09:45–11:15 OA03: ORAL ABSTRACT SESSION 3: IO CONCERNS AND TARGETED THERAPIES**
Chairs: Christine Lovly, USA & Kristen Marrone, USA
● Rouge, Lobby Level
- 09:45–09:52 **OA03.01:** Biomarkers of Autoimmune Toxicity in Metastatic SCLC Patients Receiving PD-1/PDL-1 Targeted Therapy
Apoorva Tangri, USA
- 09:52–09:59  **OA03.02:** Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with Brain Metastases Treated with Pembrolizumab
Lova Sun, USA
- 09:59–10:06 **OA03.03:** Multi-institutional Study of Pneumonitis after Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer
Timothy Sita, USA
- 10:06–10:13 **OA03.04:** Analysis of Patient Microbiome and its Correlation to Immunotherapy Response and Toxicity in Lung Cancer
Jun Zhang, USA
- 10:13–10:23 **OA03.05:** Discussant: Predictors of IO Toxicity
Kristen Marrone, USA
- 10:23–10:30 **OA03.06:** Impact of an EGFR-Lung Cancer Diagnosis on Quality of Life of Patients: Learnings from Project PRIORITY
Jill Feldman, USA
- 10:30–10:37 **OA03.07:** Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer
Jacqueline Aredo, USA
- 10:37–10:44 **OA03.08:** Clinical Utility of ctDNA Driver Genomic Alterations (GA) Directing Targeted Therapy in Untreated Advanced NSCLC Patients
Benjamin Besse, France

- 10:44–10:51 **OA03.09:** Overall Survival in Patients with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: An Update of the GioTag Study
Christoph Weinlinger, Austria
- 10:51–11:01 **OA03.10:** Discussant: Targeted Therapies: Partnerships, Inequities, and Best Therapies
Christine Lovly, USA
- 11:01–11:15 Q&A

 **GS08**

- 11:30–12:30 GS08: CLOSING PLENARY**
Chairs: Heather Wakelee, USA, Jyoti Patel, USA, Jessica Donington, USA
● Imperial Ballroom, B2 Level
- 11:30–11:45 **GS08.01:** Novel Tumor Biomarkers and Tumor Immune Profiling
Kurt Schalper, USA
- 11:45–12:00 **GS08.02:** Microbiome and Implications for Response to IO
Thomas Gajewski, USA
- 12:00–12:15 **GS08.03:** Treatment of Oligometastatic Disease Denovo and at Progression with Driver Mutations, on IO or Neither
Puneeth Iyengar, USA and Luda Bazhenova, USA
- 12:15–12:30 **GS08.04:** Closing Remarks
Heather Wakelee, USA & Jyoti Patel, USA

GS09
 LIGHT LUNCH PROVIDED

- 12:30–13:30 GS09: WOMEN IN THORACIC ONCOLOGY NETWORKING LUNCH**
● Rouge, Lobby Level
- GS09.01:** An Unscripted Life: Using Improvisational Theater Techniques to Help Women in Medicine Claim Power, Collaborate and Communicate
Katie Watson, USA



Poster Presentations

P1

P1.01: Clinical Application of Plasma miR-34b-3p and miR-302a-5p in the Diagnosis of Non-Small Cell Lung Cancer

Yang Liu, China

P1.02: Chemotherapy with VMAT (Volumetric Modulated Arc Therapy) Radiation Therapy for Poor Risk- Stage IIIA-C NSCLC Patients

Yu Zhou, USA

P1.03: Survival Benefit of Surgically Resected Occult N2 (c-N0,1 and p-N2) Non-Small-Cell Lung Cancer

Masahiko Harada, Japan

P1.04: Combined Effects of HDAC Inhibitor and Metalloproteinase Inhibitor on Invasion and Growth of Non-Small Cell Lung Cancer

Yu Zhang, China

P1.05: Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on Anti-PD-1 Therapy

Megan Randall, USA

P1.06: An Overview of Lung and Breast Cancer Using the National Cancer Database

Leigh Deshotels, USA

P1.07: External Peer Review of the Western New South Wales Lung Cancer Service: A Unique Regional and Rural Australian Experience

Sugama Mallawathantri, Australia

P1.08: Immunophenotyping of CD 146 Expression T cells in Lung Cancer Patients

Ayobami Olajuyin, China

P1.09: Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation in NSCLC

Davide Brocco, Italy

P1.10: Inflammatory Signature Difference in Rural Urban and Regional Occupational Exposure in Lung Cancer

Paul Walker, USA

P1.11: Post-PACIFIC Trial Era: Patterns of Outcomes and Toxicities from a Single Private Institution in a Developing Country

Daniel Przybysz, Brazil

🏆 P1.12: Demographics and Survival in Malignant Pleural Mesothelioma: Analysis of SEER Data

Nwabundo Anusim, USA

P1.13: Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma

Idrees Mian, USA

P1.14: Immune Profiling Data and Mutational Status Improves Prediction of Risk of Death in Non-Small Cell Lung Carcinoma

Edwin Parra, USA

P1.15: The Presence of Secondary Follicles in Early Stage Lung Adenocarcinoma Reflects Disease Burden

Rebecca Obeng, USA

P1.16: A Study on Clinicopathological Features and Diagnostic Methods of ALK Fusion-Positive Non-Small Cell Lung Cancer in Korea

Bong Kyung Shin, Korea

P1.17: Comparison of Genetic Profiles of Pulmonary Sarcomatoid Carcinoma (PSC) Between Asian and Western Populations

Yijia Guo, China

P1.18: MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer

Dan Yan, USA

P1.19: Lung Cancer Screening Initiative and Identification of Novel Blood Biomarkers for Early Detection of Lung Cancer

Shreya Deb, USA

P1.20: Metabolic Responses to Metformin in Early-Stage NSCLC Treated with Definitive Radiotherapy: Results of a Phase II Trial

Stephen Chun, USA

P1.21: RNA Pathway Enrichment in Serum Based Mass Spectroscopy Prognostic Analyses

Mary Fidler, USA

P1.22: The Lung Microbiome and Metabolome are Altered in Lung Cancer Patients

Frank Weinberg, USA

Poster Presentations

! Please note: Poster presentations are not certified for CME credit.

Poster Discussion (PD) Posters are highlighted in the Poster Discussion Session on Friday, October 11 from 15:45 – 16:45 in Imperial Ballroom, B2 Level.

PD.01

PD01.02: Oncologists' Management of Advanced NSCLC: A Simulation-Based Performance Assessment

Ann Carothers, USA

PD01.03: Changes in Immune Checkpoints Landscape Associated with TGF- β Induced EMT in Lung Adenocarcinoma

Hita Moudgalya, USA

PD01.04: CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC

David R. Spigel, USA

PD01.05: CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients

Bruce E. Johnson, USA

PD01.06: CANOPY-2: Phase 3 Study of Canakinumab plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC

Bijoyesh Mookerjee, USA

PD01.08: Incidence and Predictors Associated with the Development of Peripheral Neuropathy in Non-Small Cell Lung Cancer Patients

Jerzy Tyczynski, USA

PD01.09: Incidence and Predictors Associated with the Development of Pneumonitis in Non-Small Cell Lung Cancer Patients.

Jerzy Tyczynski, USA

PD01.10: Diagnostic Non-Invasive Biopsy Can Substitute Conventional Tissue Dependent Procedures in Suspected Cases of Lung Cancer

Dadasaheb Akolkar, India

PD01.11: Artificial Intelligence Can Detect Lung Cancer from High Resolution Microscopic Images of Conditioned Peripheral Blood

Dadasaheb Akolkar, India

PD01.13: Stereotactic Modulating Radiation Therapy (SMRT) for Oligo-Metastatic Non-Small Cell Lung Cancer

Joseph R. Kelley, USA

PD01.14: Targeting the Chemoradiation Resistance of Lung Cancers with KRAS/TP53 Co-mutations

Henning Willers, USA

PD01.15: Raman Spectroscopy and NIR Spectroscopy as Possible Aid in Localisation of Solitary Pulmonary Nodules

Jiri Votruba, Czech Republic

PD01.17: Successful Implementation of a Free Lung Cancer Screening Program in a Rural Tertiary Care Hospital Setting

Michael J. Minarich, USA

PD01.18: Beneficial Effect of Antibiotic Use in Patients with Stage IV NSCLC Treated with Immune Checkpoint Inhibitors

Chao Huang, USA

PD01.19: Lung Cancer Strategist Program: A Novel Care Delivery Model to Improve Timeliness of Diagnosis and Treatment

William W. Phillips, USA

PD01.20: Medicaid Outcome Inequalities in Small Cell Lung Cancer

Stephen Chun, USA



IASLC 2020

Meetings Schedule

Sixth AACR-IASLC International Joint Conference: Lung Cancer

Jan. 11-14, 2020 | San Diego, CA | #Lung20

IASLC 2020 Targeted Therapies of Lung Cancer

Feb. 19-22, 2020 | Santa Monica, CA
#TTLC20

European Lung Cancer Congress 2020

April 15-18, 2020 | Geneva, Switzerland
#ELCC20

Lung Cancer Hot Topic: Liquid Biopsy

May 2020 | Baltimore, MD

IASLC 2020 World Conference on Lung Cancer

August 9-12, 2020 | Singapore | #WCLC20

IASLC 2020 North America Conference on Lung Cancer

October 15-17, 2020 | Chicago, IL
#NACLC20

Lung Cancer Hot Topic: Immunotherapy

November 2020

CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 linkedin.com

 iaslc.lung

 IASLC



IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

Author Index



Author Index

Authors in Bold = Presenting Author

A		Datar Rajan.....	PD01.10, PD01.11
Abdullaev Ziad.....	P1.13	Datta Vineet.....	PD01.11
Abu-Hejleh Taher.....	OA03.04	Davis Christiana.....	OA03.02
Adhav Archana.....	PD01.10, PD01.11	Deb Shreya.....	P1.19
Aggarwal Charu.....	OA03.02	De Forcrand Claire.....	PD01.20
Ahmed Rafi.....	P1.15	De Kievit Frank.....	OA03.08
Ahmed Tamjeed.....	OA01.04	Denlinger Crystal.....	OA01.06
Akolkar Dadasaheb.....	PD01.10, PD01.11	Denogean Jennifer.....	OA02.07
Alam Naveed.....	P1.07	Deryckere Deborah.....	P1.18
Aldea Mihaela.....	OA03.08	Desai Jayesh.....	OA01.06
Al-Jumayli Mohammed.....	PD01.19	Deshotels Leigh.....	P1.06
Alston-Johnson Devena.....	OA02.06	De Tursi Michele.....	P1.09
Anderson Austin.....	P1.19	Deudon Stephanie.....	PD01.05
Antonoff Mara B.....	OA02.09	Di Marino Pietro.....	P1.09
Anusim Nwabundo.....	P1.12	Dorta Miriam.....	OA03.08
Ardizzoni Andrea.....	PD01.04	Dothard Andrew.....	OA01.04
Aredo Jacqueline.....	OA03.07	Dowlati Afshin.....	OA01.03
Armitage Julee.....	PD01.20	D'Rummo Kevin.....	PD01.19
Atwood Sarah.....	PD01.02	Duffy Mary.....	P1.07
		Durm Greg.....	OA01.06
B		E	
Bajor David.....	OA01.03	Earp H. Shelton.....	P1.18
Balagurunathan Yoganand.....	OA02.08	Eastman Evan.....	OA03.04
Baldwin David.....	P1.07	Efird Jimmy.....	OA01.03
Barlesi Fabrice.....	PD01.04	Elkins Ivy.....	OA03.06
Barone Claudia.....	OA02.01, OA02.02	Eschrich Steven.....	OA02.05, OA02.08
Basu Roy Upal.....	OA03.06		
Basu Sanjib.....	P1.05	F	
Batus Marta.....	OA01.02, OA03.01, P1.02, P1.05, P1.21	Fabro Alexandre.....	P1.14
Baumann Michael.....	PD01.15	Fakih Marwan.....	OA01.06
Baum Jason.....	PD01.04	Falchook Gerald.....	OA01.06
Bauml Joshua.....	OA03.02	Fang Jian.....	OA01.08
Bearden Caitlin.....	OA02.06	Farhat Cecilia.....	P1.14
Begnell Joel.....	P1.07	Faulkner Neil.....	PD01.14
Behera Madhusmita.....	P1.15	Feigenberg Steven.....	OA03.02
Benes Cyril.....	PD01.15	Feldman Jill.....	OA03.06
Berei Joseph.....	P1.19	Felip Henriqueta.....	OA01.10, PD01.05
Berman Abigail.....	OA03.02	Ferguson Frances.....	P1.07
Besse Benjamin.....	OA03.08	Fidler Mary.....	OA01.02, OA03.01, P1.02, P1.05, P1.21
Betancourt Sonia L.....	OA02.09	Figuera Anita.....	OA03.06
Biswas Tithi.....	OA01.03	Flynn Peter.....	P1.07
Bologna Giuseppina.....	P1.09	Fong Kwun.....	P1.07
Bonomi Philip.....	OA01.02, OA03.01, P1.02, P1.05, P1.21	Fox Sam.....	PD01.20
Borghaei Hossein.....	OA01.01	Franklin Patricia.....	OA02.01, OA02.02
Borgia Jeffrey.....	OA01.02, OA03.01, P1.05, P1.21, PD01.03	Frye Stephen.....	P1.18
Bradbury Lauren.....	P1.07	Fughhi Ibtihaj.....	P1.05
Bradley Jeffrey.....	OA03.03	Fuller Clifton.....	PD01.21
Brandman Scott.....	OA02.07	Fulmali Pooja.....	PD01.10, PD01.11
Brocco Davide.....	P1.09	Fulmali Pradip.....	PD01.10, PD01.11
Brúha Tomáš.....	PD01.16	Furqan Muhammad.....	OA03.04
Byers Lauren.....	PD01.21		
Byrom Michael.....	P1.07	G	
C		Gadgeel Shirish.....	OA01.01
Cady Nicole.....	OA03.04	Gandhi Saumil.....	PD01.21
Cao Rui.....	P1.17	Gao Shaojian.....	P1.13
Capelozzi Vera.....	P1.14	Gao Wen.....	OA01.08
Carothers Ann.....	PD01.02	Garassino Marina.....	OA01.01
Castro Gilberto De.....	PD01.05	Garje Rohan.....	OA03.04
Catalano Paul.....	PD01.20	Garon Edward B.....	OA01.07, PD01.04
Chaaya Gerard.....	P1.06	Gazzah Anas.....	OA03.08
Chan Carlos.....	OA03.04	Gentile Michelle.....	OA03.03
Chang Joe.....	P1.20, PD01.21	Gerard David.....	PD01.03
Chang Won Chul.....	P1.16	Gil Ferreira Carlos.....	P1.11
Chau Justin.....	OA03.04	Gillies Robert.....	OA02.05, OA02.08
Chen Gongyan.....	OA01.08	Gilmore Brendan.....	OA03.01
Cheng Ying.....	OA01.01	Giovannini Monica.....	OA01.07
Cho Byoung Chul.....	PD01.04	Goto Yasushi.....	PD01.04, PD01.06
Choong Ee Siang.....	P1.07	Govindan Ramaswamy.....	OA01.06
Chun Stephen.....	P1.20, PD01.21	Graham Douglas.....	P1.18
Ciociola Elizabeth.....	OA02.06	Gray Jhanelle E.....	OA02.05
Cohen Roger.....	OA03.02	Grecea Alina-Miruna.....	OA03.08
Colson Yolonda L.....	PD01.20	Greco Michael.....	OA01.08
Corsini Erin M.....	OA02.09	Green Emma.....	OA03.08
Cufer Tanja.....	OA03.09	Greystoke Alastair.....	PD01.05
		Grivet Flávia.....	P1.11
D		Groen Harry J. M.....	OA01.07
Dai Qun.....	OA03.04	Gucalp Rasim.....	OA03.09
Dalurzo Liliana.....	OA01.10	Guerrero Thomas.....	P1.20
Darrow Kaleb.....	PD01.14	Guo Yijia.....	P1.17
		Gurtner Kristin.....	PD01.15
		Guvenis Albert.....	OA02.05

H

Habartova Lucie.....	PD01.16
Hadid Walid.....	PD01.18
Hahn Stephen.....	PD01.21
Halmos Balazs.....	OA03.09
Han Chengbo.....	P1.17
Han Ji-Youn.....	OA01.07
Hanna Wahid.....	PD01.14
Han Summer.....	OA03.07
Hao Desiree.....	OA03.09
Harada Masahiko.....	P1.03
Hardy Ashley.....	PD01.18
Hassan Raffit.....	P1.13
Hassanzadeh Comron.....	OA03.03
Heidel Robert E.....	PD01.14
Henry Haby.....	OA01.06
Henderson Louise.....	OA02.06
Henry Leonard.....	PD01.18
Heymach John.....	P1.20
Hida Toyooki.....	OA01.07
Hirsch Fred.....	OA01.10
Hochmair Maximilian J.....	OA03.09
Hofferberth Sophie C.....	PD01.20
Hollenbeck Gina.....	OA01.10
Hollman Tamara.....	P1.07
Hong David.....	OA01.06
Horio Hirotooshi.....	P1.03
Houghton Baerin.....	OA01.01
Howarth Karen.....	OA03.08
Howell Kristin.....	OA01.10
Huang Chao.....	PD01.19
Huang Jian'An.....	OA01.08
Huang Letian.....	P1.17
Huelse Justus.....	P1.18
Hu Guoqiang.....	OA01.08

I

Ionescu Filip.....	P1.12
Irtelli Luciana.....	P1.09

J

Jaiyesimi Ishmael.....	P1.12
Jang Mei.....	P1.14
Jeter Melenda.....	P1.20
Johnson Bruce E.....	PD01.05
Jones Ruth.....	P1.07
Jonge Maja De.....	OA01.07
Jovelet Cecile.....	OA03.08

K

Kadkhoda Haleh.....	PD01.02
Kalkbrenner Kara.....	OA02.07
Kang Kylie.....	OA01.03
Kao Steven.....	P1.07
Kelley Joseph R.....	PD01.14
Kennedy Teri.....	OA03.06
Kerr Keith.....	OA01.10
Khan Javed.....	P1.13
Khan Shabista.....	PD01.10, PD01.11
Kim Edward.....	OA01.10
Kim Han Kyeom.....	P1.16
Kio Ebenezer.....	PD01.18
Kollipara Revathi.....	OA01.02, P1.05
Komaki Ritsuko.....	P1.20
Komiya Takefumi.....	OA02.03 , P1.06
Koong Albert.....	P1.20
Korah Bobby.....	P1.20
Koshy Suja.....	P1.20
Krause Mechthild.....	PD01.15
Krauss John.....	OA01.06
Kruser Tim.....	OA03.03
Kuckovic Adijan.....	P1.19
Kunder Christian.....	OA03.07
Kuo James.....	OA01.06
Kurata Takayasu.....	OA01.01

L

Lacroix Ludovic.....	OA03.08
Lamberts Virginie.....	OA03.08
Langer Corey.....	OA01.01, OA03.02
Lantuejoul Sylvie.....	OA01.10
Lanuti Paola.....	P1.09
Lathan Christopher.....	PD01.20
Lavaud Pernelle.....	OA03.08
Leung Mimi.....	PD01.04
Levin William.....	OA03.02
Liao Zhongxing.....	P1.20, PD01.21

Li Bob.....	OA01.06
Lim Darren Wan Teck.....	PD01.06
Lin Jianxin.....	OA01.01
Lin Steven.....	P1.20
Liu Yang.....	P1.01
Li Wen-Rong.....	OA01.02
Li Xiao.....	OA01.08
Li Xingya.....	OA01.08
Long Jason.....	OA02.06
Long Jieran.....	OA01.08
Louveau Anne Laure.....	PD01.05
Lu Shun.....	PD01.04
Lycan Jr. Thomas.....	OA01.04

M

Machado-Rugolo Juliana.....	P1.14
Machtay Mitchell.....	OA01.03
Macleay Mooreen.....	P1.07
Mafori Thiago.....	P1.11
Ma Jietao.....	P1.17
Malet Isabelle.....	PD01.06
Mallawathantri Sugamya.....	P1.07
Mangalam Ashutosh.....	OA03.04
Marchi Pedro De.....	PD01.04
Marchisio Marco.....	P1.09
Marmarelis Melina.....	OA03.02
Marsee Mathew K.....	PD01.18
Martell Sandra.....	P1.19
Märten Angela.....	OA03.09
Martin-Romano Patricia.....	OA03.08
Marwaha Gaurav.....	P1.02
Massard Christophe.....	OA03.08
Mathias Clarissa.....	OA01.10
Mayo Ray.....	P1.20
Mayorchak Yaroslav.....	P1.07
Mazumder Debasish.....	PD01.08, PD01.09
Meek Mollie.....	OA02.01
Mettienien Markku.....	P1.13
Mezquita Laura.....	OA03.08
Mian Idrees.....	P1.13
Minarich Michael J.....	PD01.18
Minsky Bruce.....	PD01.21
Miscia Sebastiano.....	P1.09
Mitchell Kyle G.....	OA02.09
Mohamed Abdallah.....	PD01.21
Mohindra Nisha.....	OA03.03
Montella Tatiane.....	P1.11
Mookerjee Bijoyesh.....	PD01.04, PD01.06
Morabito Alessandro.....	OA03.09
Morris Clive.....	OA03.08
Morrow Betsy.....	P1.13
Morrow Phuong Khanh.....	OA01.06
Moudgalya Hita.....	OA01.02, PD01.03
Mouhaer Sylvie Le.....	OA01.07
Muesse Jason.....	OA02.01, OA02.02

N

Nace Mercer Keri.....	OA03.04
Nagai Maria.....	P1.14
Naltet Charles.....	OA03.08
Ngang Jude.....	OA01.06
Ngarmchamnanrith Gataree.....	OA01.06

O

Obeng Rebecca.....	P1.15
Odell David D.....	PD01.20
Olajuyin Adefunke Kafayat.....	P1.08
Olajuyin Ayobami.....	P1.08
Orlov Sergey V.....	OA01.07
Osborne Ricahrd.....	P1.07
Owonikoko Taofeek.....	P1.15

P

Pack Svetlana.....	P1.13
Padda Sukhmani.....	OA03.07
Pageilan John.....	OA02.01 , OA02.02
Pan Tinsu.....	OA02.09
Papademetriou Eros.....	PD01.08, PD01.09
Papadimitrakopoulou Vassiliki A.....	OA01.01, PD01.06
Parker Rebecca.....	P1.18
Parra Edwin.....	P1.14
Passos Vanessa.....	PD01.05
Patel Shoeb.....	PD01.10, PD01.11
Patil Darshana.....	PD01.10, PD01.11
Patil Revati.....	PD01.10, PD01.11
Patil Sanket.....	PD01.10, PD01.11
Paz-Ares Luis.....	OA01.01, PD01.04, PD01.06
Pei Lei.....	PD01.19



Pender Lori.....PD01.02
 Perez Morales Jaileene**OA02.08**
 Peri Marta.....P1.09
 Peterson-Incorvaia Michael.....OA02.07
 Petty WilliamOA01.04
 Pezzi Todd.....PD01.21
 Phillips Martin.....P1.07
 Phillips William W**PD01.20**
 Pietanza CetherineOA01.01
 Pillai RathiP1.15
 Piperdi BilalOA01.01
 Pisters KatherinePD01.21
 Planchard David.....OA03.08
 Postmus PieterOA01.10
 Potluri Ravi.....PD01.08, PD01.09
 Powell Charles.....OA01.10
 Prabhakar Charles.....P1.07
 Price Timothy.....OA01.06
 Prichard PabloOA02.07
 Przybysz Daniel.....**P1.11**
 Punwani Ravi.....P1.07
 Puri Neelu.....P1.19

R

Racherla Kavya Sri.....P1.19
 Rai RajathP1.07
 Ramalingam SureshOA01.10, P1.15
 Ranade Anantbhushan.....PD01.10, PD01.11
 Randall Megan.....**P1.05**
 Raqib AnkurP1.21
 Rasmussen Erik.....OA01.06
 Rauch GregoryOA02.09
 Reck Martin.....PD01.06
 Reguart Noemi.....OA01.07
 Remon Jordi.....OA03.08
 Richeimer KristinOA01.10
 Ritz Ethan.....P1.02
 Rivera M. Patricia.....**OA02.06**
 Roach MichaelOA03.03
 Roberts Nathan.....**OA01.04**
 Robeva Anna.....OA01.07
 Robinson CliffordOA03.03
 Rodriguez-Abreu DelvysOA01.01
 Ross JosephP1.19
 Rouleau Etienne.....OA03.08
 Rufino RogerioP1.11
 Ruiz JimmyOA01.04

S

Samson PamelaOA03.03
 Savoro RohanOA03.03
 Scagliotti GiorgioOA01.10
 Schabath Matthew.....OA02.05, OA02.08
 Schulz WilliamP1.19
 Schwartz DavidPD01.21
 Seto TakashiOA01.07
 Shahi Shailesh.....OA03.04
 Sharma NitikaP1.10
 S. Heist Rebecca.....**OA01.07**
 Shi Jianhua.....OA01.08
 Shima Toshiyuki.....P1.03
 Shin Bong Kyung**P1.16**
 Shi Yuankai**OA01.08**
 Shroff Girish.....OA02.09
 Shukla Vershalee**OA02.07**
 Shu Yongqian.....OA01.08
 Sica Gabriel.....P1.15
 Simeone Pasquale.....P1.09
 Sims CynthePD01.11
 Singh AditiOA03.02
 Singh KaranvirP1.07
 Sita Timothy**OA03.03**
 Sites SamanthaOA02.06
 Skinner HeathP1.20
 Smeltzer Matthew.....**OA01.10**
 Smit Egbert F.....OA01.07
 Solomon BenPD01.05
 Song ZhipengP1.01
 Soo Ross A.....OA01.10, OA03.09
 Souquet Pierre-JeanOA01.07
 Spigel David R.....**PD01.04**
 Sreenivasappa ShylendraP1.19
 Srinivasan Ajay.....PD01.10, PD01.11
 Steliga MatthewOA02.01, OA02.02
 Strickler John.....OA01.06
 Stringfield OlyaOA02.08
 Stroud GeoffreyP1.10
 Sun LiP1.17
 Sun Lova**OA03.02**

T

Takagaki TerezaP1.14
 Tan Daniel S. WOA01.07, PD01.05
 Tangri Apoorva**OA03.01**
 Tan YanOA02.05
 Tarhoni Imad.....**OA01.02**, OA03.01, P1.05, PD01.03
 Taylor Meghan.....OA01.10
 Taylor Tina.....OA02.06
 Terra RicardoP1.14
 Thomas Michael.....PD01.04
 Thuraisingam KandeepanP1.07
 Tinari Nicola.....P1.09
 Tingquist NicholasOA02.01, **OA02.02**
 Tolekidis George.....P1.02
 Topping DonnaPD01.02
 Tsuboi Masahiro.....OA01.10
 Tunali Ilke.....**OA02.05**, OA02.08
 Turley Kim.....P1.07
 Turner J Francis.....PD01.14
 Tyagi Rohit.....PD01.08, PD01.09
 Tyczynski Jerzy.....**PD01.08**, **PD01.09**
 Tyrlik Tyler.....OA02.07

V

Vandyk Magda.....OA02.06
 Vansteenkiste Johan.....OA01.07
 Varella-Garcia Marilella.....OA01.10
 Vitali Connie.....P1.19
 Von Holzen Urs WPD01.18
 Votruba Jiri**PD01.16**

W

Wakelee HeatherOA03.07
 Waldron-Lynch MaeveOA01.07
 Walker Paul.....**P1.10**
 Wang Andy.....OA02.03
 Wang Donglin.....OA01.08
 Wang Fen.....PD01.19
 Wang Lara.....OA03.09
 Wang Xiaodong.....P1.18
 Wang Ziqi.....P1.08
 Waqar SaiamaOA03.03
 Weaver Leroy.....PD01.18
 Wei JunP1.13
 Weinberg Frank**P1.22**
 Weiner GeorgeOA03.04
 Weinlinger Christoph.....**OA03.09**
 Weissman Joel S.....PD01.20
 Welsh JamesPD01.21
 Willers Henning.....**PD01.15**
 Wistuba Ignacio.....OA01.10
 Wolf JuergenOA01.07
 Wood KelseyOA01.10
 Wu CarolOA02.09
 Wynes Murry.....OA01.10


Y

Yadav Meeta.....OA03.04
 Yamamichi TakashiP1.03
 Yan Dan.....**P1.18**
 Yang Cheng-TaOA03.09
 Yang James C-H.....OA03.09
 Yang James Chih-HsinPD01.04
 Yang ShengOA01.08
 Yu Huiqing.....OA01.08

Z

Zakharia YousefOA03.04
 Zewen ZhuPD01.04
 Zhang Jun**OA03.04**
 Zhang LiangmingOA01.08
 Zhang Xiangyan.....P1.17
 Zhang Xiaojun.....P1.08
 Zhang Yu**P1.04**
 Zhao Jianzhu.....P1.17
 Zhao Yanqiu.....OA01.08
 Zhao ZhingruP1.08
 Zheng Rongsheng.....OA01.08
 Zheng SuhuaP1.01
 Zhou NicolasOA02.09
 Zhou Yu.....**P1.02**
 Zhu BoOA01.08
 Zhu ZewenPD01.06
 Zielinski Robert.....P1.07

Advertiser and Exhibitor Information



ADVERTISER AND EXHIBITOR INFORMATION



 @IASLC

 iaslc.lung

 facebook.com/IASLC

 IASLC

 IASLC


#NACLC19

naclc2019.IASLC.org

Conference Advertisers and Exhibitors

PLATINUM

AMGEN[®]



MERCK



NOVARTIS

GOLD

Genentech

A Member of the Roche Group

SILVER

AstraZeneca


BRONZE



ONCOLOGY

Exhibit Floor Plan

The Exhibition and Poster Hall is located on B2 Level.



Exhibitor Listings

Company	Booth #
Genentech	1
Amgen	2
Merck	3
Inivata	4
Bayer	5
Lilly Oncology	5a
Novartis	6
IASLC	7

Company	Booth #
Takeda	8
Tempus	8a
United Therapeutics	9
Bayer (IXM)	10
Boehringer Ingelheim	11
Novocure	12
Guardant	13
AstraZeneca	14
Morhaf Al Achkar - Roads to Meaning and Resilience with Cancer	15

Exhibitor Descriptions

Booth 2


AMGEN® Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient's life – not just their cancer journey – so they can take control of their lives. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them. At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

For more information, follow us on www.twitter.com/amgenoncology.

Booth 14

AstraZeneca  AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Booth 5 | Booth 11

 Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women's health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.


Booth 11

 **Boehringer Ingelheim** At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.


Booth 1

Genentech *A Member of the Roche Group* Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

Booth 13

 **GUARDANT**™ Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Since its launch, Guardant360 has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 27 of the NCC Network centers.

Booth 7

IASLC  The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Exhibitor Descriptions

Booth 4



Inivata is a leader in liquid biopsy. Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.

Inivata is a leader in liquid biopsy. Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.

Booth 5a



For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. We're determined to continue making life better for all those affected by cancer around the world. To learn more, please visit www.LillyOncology.com.

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. We're determined to continue making life better for all those affected by cancer around the world. To learn more, please visit www.LillyOncology.com.


Booth 3



For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

Booth 15



Morhaf Al Achkar – Roads to Meaning and Resilience with Cancer This book tells the stories of 39 patients with incurable lung cancer. It aims to help patients, families, and healthcare providers understand the experience of living with cancer. The author is a family doctor, teacher, and researcher who is a stage 4 lung cancer patient himself. He is patient #40.

Booth 6



At Novartis, we are reimagining medicine to produce breakthroughs and address unmet needs for patients with devastating diseases, including genetic disorders and certain deadly cancers. These efforts are done in collaboration with scientists, physicians, academia, industry partners and patients.

At Novartis, we are reimagining medicine to produce breakthroughs and address unmet needs for patients with devastating diseases, including genetic disorders and certain deadly cancers. These efforts are done in collaboration with scientists, physicians, academia, industry partners and patients.

Booth 12



Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

Booth 8



ONCOLOGY

Takeda is a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 237-year history. Our mission is to strive towards better health and a brighter future for people worldwide through leading innovation in medicine. Takeda's Global Oncology Business Unit endeavors to deliver novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion for improving the lives of patients. Visit TakedaOncology.com.

Takeda is a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 237-year history. Our mission is to strive towards better health and a brighter future for people worldwide through leading innovation in medicine. Takeda's Global Oncology Business Unit endeavors to deliver novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion for improving the lives of patients. Visit TakedaOncology.com.

Booth 8a



Tempus is bringing the power of artificial intelligence to healthcare by building the world's largest library of molecular and clinical data and a platform to make that data accessible and useful. We provide genomic sequencing services and analyze molecular and therapeutic data at scale to empower physicians and researchers to make real-time, data-driven decisions.

Tempus is bringing the power of artificial intelligence to healthcare by building the world's largest library of molecular and clinical data and a platform to make that data accessible and useful. We provide genomic sequencing services and analyze molecular and therapeutic data at scale to empower physicians and researchers to make real-time, data-driven decisions.

Booth 9



United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.



2020 World Conference on Lung Cancer

August 9-12, 2020 | Singapore

Conquering Thoracic Cancers Worldwide

Join us in **Singapore** for **WCLC 2020!**

August 9-12, 2020



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



www.IASLC.org

#WCLC20

IASLC



2020 North America Conference on Lung Cancer

OCTOBER 15-17, 2020 | CHICAGO, ILLINOIS, USA



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



www.IASLC.org

#NACL20

reimagining medicine

for **Lung
Cancer**
patients

Come visit us at
Booth 6



Scan to explore
our pipeline

